Cabaletta Bio Stock Analysis

Cabaletta Stock Analysis Notes

About 75.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 1.73. Some equities with similar Price to Book (P/B) outperform the market in the long run. Cabaletta Bio recorded a loss per share of 2.4. The entity had not issued any dividends in recent years. Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania. Cabaletta Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 57 people. For more info on Cabaletta Bio please contact the company at 267 759 3100 or go to https://www.cabalettabio.com.

Cabaletta Bio Investment Alerts

Cabaletta Largest EPS Surprises

View All Earnings Estimates

Cabaletta Bio Environmental, Social, and Governance (ESG) Scores

Cabaletta Stock Institutional Investors

Note, although Cabaletta Bio's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Cabaletta Market Capitalization

The company currently falls under 'Small-Cap' category with a current market capitalization of 249.33 M.

Cabaletta Profitablity

Management Efficiency

Cabaletta Bio has return on total asset (ROA) of (0.5182) % which means that it has lost $0.5182 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.0106) %, meaning that it created substantial loss on money invested by shareholders. Cabaletta Bio's management efficiency ratios could be used to measure how well Cabaletta Bio manages its routine affairs as well as how well it operates its assets and liabilities. As of February 5, 2026, Return On Tangible Assets is expected to decline to -0.76. The current year's Return On Capital Employed is expected to grow to -0.87. At present, Cabaletta Bio's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 7.5 M, whereas Total Assets are forecasted to decline to about 133.7 M.

Technical Drivers

As of the 5th of February, Cabaletta Bio shows the risk adjusted performance of 0.0371, and Mean Deviation of 4.82. Cabaletta Bio technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.

Cabaletta Bio Price Movement Analysis

Cabaletta Bio Insider Trading Activities

Cabaletta Bio Outstanding Bonds

Cabaletta Bio Predictive Daily Indicators

Cabaletta Bio Forecast Models

Cabaletta Bio's time-series forecasting models are one of many Cabaletta Bio's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Cabaletta Bio's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Cabaletta Bio Bond Ratings

Cabaletta Bio financial ratings play a critical role in determining how much Cabaletta Bio have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for Cabaletta Bio's borrowing costs.

Cabaletta Bio Debt to Cash Allocation

Cabaletta Bio currently holds 15.6 M in liabilities. Cabaletta Bio has a current ratio of 14.92, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Cabaletta Bio's use of debt, we should always consider it together with its cash and equity.

Cabaletta Bio Total Assets Over Time

Cabaletta Bio Assets Financed by Debt

The debt-to-assets ratio shows the degree to which Cabaletta Bio uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.

Cabaletta Bio Debt Ratio

9.21

It appears most of the Cabaletta Bio's assets are financed through equity. Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the Cabaletta Bio's operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of Cabaletta Bio, which in turn will lower the firm's financial flexibility.

Cabaletta Bio Corporate Bonds Issued

Cabaletta Net Debt

Stock analysis is the technique used by a trader or investor to examine and evaluate how Cabaletta Bio prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Cabaletta shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Cabaletta Bio. By using and applying Cabaletta Stock analysis, traders can create a robust methodology for identifying Cabaletta entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Cabaletta analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Cabaletta analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Cabaletta Bio stock analysis indicators help investors evaluate how Cabaletta Bio stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Cabaletta Bio shares will generate the highest return on investment. By understating and applying Cabaletta Bio stock analysis, traders can identify Cabaletta Bio position entry and exit signals to maximize returns.

When running Cabaletta Bio's price analysis, check to measure Cabaletta Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cabaletta Bio is operating at the current time. Most of Cabaletta Bio's value examination focuses on studying past and present price action to predict the probability of Cabaletta Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cabaletta Bio's price. Additionally, you may evaluate how the addition of Cabaletta Bio to your portfolios can decrease your overall portfolio volatility.